The recent executive order to reclassify cannabis from a Schedule I to a Schedule III drug represents a historic recalibration of drug policy in the United States. For decades, federal law has treated cannabis as having no accepted medical use and a high potential for abuse ~ a stance increasingly at odds with scientific evidence, state-level legislation, and public sentiment. By formally acknowledging cannabis as a substance with medical validity and a moderate-to-low potential for dependency, the order bridges a long-standing divide between federal policy and societal realities.

The practical implications are profound. Moving cannabis to Schedule III lowers barriers for scientific and medical research, enabling studies into its potential therapeutic benefits. For patients suffering from chronic pain, cancer, seizure disorders, and service-related injuries, this represents more than bureaucratic adjustment ~ it is an acknowledgment of their lived experience. Equally significant are the economic consequences: state-licensed dispensaries, long restricted from........

© The Statesman